Eli Lilly and Company (LLY)
| Market Cap | 925.43B |
| Revenue (ttm) | 59.42B |
| Net Income (ttm) | 18.41B |
| Shares Out | 895.38M |
| EPS (ttm) | 20.44 |
| PE Ratio | 50.56 |
| Forward PE | 33.21 |
| Dividend | $6.00 (0.58%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | 3,447,003 |
| Open | 1,046.39 |
| Previous Close | 1,046.12 |
| Day's Range | 1,022.32 - 1,051.48 |
| 52-Week Range | 623.78 - 1,111.99 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 1,057.89 (+2.35%) |
| Earnings Date | Oct 30, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,057.89, which is an increase of 2.35% from the latest price.
News
Companies Cut Prices For Blockbuster Weight-Loss Drugs
In this week's edition of InnovationRx, we look at the price cuts for blockbuster weight-loss drugs, the Forbes 30 Under 30 Healthcare list, the coming barriers to getting vaccines, and more. To get i...
1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year
Eli Lilly has seen revenue soar thanks to its blockbuster weight loss drug portfolio. Lilly and Novo Nordisk dominate this market, which has seen high demand.
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded indica...
GXP-Storage Appoints Former Eli Lilly Global Clinical Research Executive Chris Otto to Board of Directors
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Chris Otto brings over three decades of global clinical research experience to the Board of Directors of GXP-Storage.
2 Trillion-Dollar Dividend Stocks to Buy and Hold for 10 Years
These two market leaders boast significant growth prospects in their niches. They increased their payouts at a good clip over the past decade.
Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Howard University Receives $10M Gift from Lilly Endowment to Support Efforts to Advance Over 155 Years of Black Theological Education
Washington, D.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Howard University has received a grant of $10 million from Lilly Endowment Inc. through its Pathways for Tomorrow Initiative. The funding will help ...
BA Flies on Strong Commentary, WDC & STX Price Target Hikes, LLY Boost
Boeing (BA) opened Tuesday's trading action as the stronger performer in the SPX. Diane King Hall points to commentary from the company on returning to positive free cash flow lifting the plane manufa...
Eli Lilly Trims Price of Popular Weight-Loss Drug on Its Site a Month After Trump Deal
Eli Lilly (LLY) said Monday that it's lowering the price of its popular weight-loss drug Zepbound, about a month after striking a deal with the Trump administration to lower drug costs.
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site.
Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect.
16 Quality Stocks to Own for a Volatile Market
The S&P 500 has staged an impressive rebound, but is in for more swings.
Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound
Eli Lilly is cutting prices again for those who pay cash for introductory doses of the weight-loss drug Zepbound. The lowest dose vial will cost $299 a month, that would be a saving of about $50.
Eli Lilly Lowers Weight-Loss Drug Zepbound Prices After Trump Deal
$1,086. That's the monthly cost of Zepbound before any discounts or rebates, according to Eli Lilly. The list price for Ozempic is just over $997 per month.
Eli Lilly's price cut, Thanksgiving box office, trouble for gravestone makers and more in Morning Squawk
Eli Lilly cut prices for Zepbound on its direct-to-consumer platform. The Nasdaq Composite is coming off a losing month amid AI spending concerns.
Eli Lilly cuts Zepbound price to widen access for obesity drug
Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S. patients, as demand for weight-loss therapies...
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
Eli Lilly said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect. Starting Dec. 1, cash-paying patients w...
Is Eli Lilly a Millionaire Maker?
Eli Lilly just agreed to lower the price of its blockbuster GLP-1 weight loss drug. More than half of the company's revenue comes from just two weight loss drugs.
These Are 2 of the Smartest Growth Stocks to Invest $5,000 in Today
Both of these stocks are growing by leaps and bounds. MercadoLibre boasts a cohesive ecosystem that is driving revenue and profits forward.
S&P 500 Gains and Losses Today: Intel Soars Amid Apple Deal Rumors; Eli Lilly Stock Slides
A major U.S. chipmaker got a boost from speculation that it could win a new Big Tech customer, while a high-flying pharmaceutical stock reversed some of its recent gains.
Don't expect much from Eli Lilly stock anymore, says Len Yaffee
Market expert Len Yaffee says it would be increasingly difficult for Eli Lilly (NYSE: LLY) to push higher from current levels – at least in the near-term. LLY shares have been standout performers in 2...
Prediction: This Growth Stock Could Hit a $2 Trillion Valuation by 2031
Eli Lilly's valuation may suggest that its market-beating days are behind it. However, the pharmaceutical giant still has significant momentum.
Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee
Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.
Stock Split Watch: Is Eli Lilly Next?
Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company's portfolio of weight loss drugs, which has generated blockbuster revenue.
Wall Street Breakfast Podcast: HP Downsizes To Power Up
HP (HPQ) shares dropped 6% after issuing a weak forecast and announcing up to 6,000 job cuts despite beating quarterly earnings estimates. The Trump administration secured a 71% Medicare discount on O...
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
Updated results from the Phase 3 EMBER-3 trial for Inluriyo™ (imlunestrant) alone and in combination with Verzenio® (abemaciclib) in ER+, HER2– metastatic breast cancer to be presented as a late-break...